An Analysis of the Relationship Between Preclinical and Clinical QT Interval-Related Data

Evolution of strategies to improve preclinical cardiac safety testing

(2016) Gary Gintant et al.   NATURE REVIEWS DRUG DISCOVERY

The Concordance between Nonclinical and Phase I Clinical Cardiovascular Assessment from a Cross-Company Data Sharing Initiative

(2014) Lorna Ewart et al.   TOXICOLOGICAL SCIENCES

The impact of drug-related QT prolongation on FDA regulatory decisions

(2013) Eunjung Park et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Reducing safety-related drug attrition: the use of in vitro pharmacological profiling

(2012) Joanne Bowes et al.   NATURE REVIEWS DRUG DISCOVERY

An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk

(2010) CE Pollard et al.   BRITISH JOURNAL OF PHARMACOLOGY

An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation

(2010) Gary Gintant   PHARMACOLOGY & THERAPEUTICS

Integrated risk assessment and predictive value to humans of non-clinical repolarization assays

(2009) Robert M Wallis   BRITISH JOURNAL OF PHARMACOLOGY